title: Improving hospital performance in the treatment of febrile neutropenia.
abstract: OBJECTIVE
  Febrile neutropenia (FN) remains a common and dangerous complication of cancer treatment. Guidelines from the Infectious Disease Society of America urge initiating antibiotics within 2 h of presentation. We reviewed our institution's performance to identify areas of needed improvement and to design performance improvement steps.
  
  
  METHODS
  FN management was deconstructed into discrete tasks. Experienced practitioners estimated appropriate time allowance for each task. Cycle time analysis data on a baseline cohort (baseline group) identified causes and loci of delay. Based on these data, new processes to bypass roadblocks for timely therapy were introduced. Performance monitoring continued as these changes were implemented (the transitional group) and for 20 months thereafter (the post-intervention group).
  
  
  RESULTS
  Sixty-nine episodes of FN were identified. Ten distinct improvement steps were implemented. Median time to antibiotics was reduced from 252 min, to 188 min and 118 min for the baseline, transitional, and post-intervention groups, respectively (p = 0.0002 for the baseline vs. the post-intervention group comparison). Variability was reduced with the inter-quartile range falling from 174 min (baseline) to 65 min (post-intervention). Despite improvement, there were persisting episodes of delays, due to competing priorities from other patients or decisions to postpone infusion of antibiotics until patients had been admitted. Standardized order sets eliminated improper antibiotic choices as a source of error.
  
  
  CONCLUSIONS
  Improvements in the management of FN can be accomplished and sustained by the focused study of performance of individual tasks, the design of streamlined processes by practitioners, and the ongoing review of performance with feedback to clinical departments.
authors.affiliation: DeCesaris Cancer Center, Anne Arundel Medical Center, 2001 Medical Parkway, Annapolis, MD, 21401, USA, Meisenberg@aahs.org.
authors.forename: Barry
authors.initials: B
authors.lastname: Meisenberg
authors.forename: Jan
authors.initials: J
authors.lastname: Clemons
authors.forename: John
authors.initials: J
authors.lastname: Ness
authors.forename: Nancy
authors.initials: N
authors.lastname: Faust
authors.forename: Mary
authors.initials: M
authors.lastname: Clance
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D019468:Disease Management; D061345:Early Medical Intervention / Q000379:methods / Q000592:standards; D064147:Febrile Neutropenia / Q000209:etiology / Q000628:therapy; D005260:Female; D019983:Guideline Adherence / Q000592:standards / Q000706:statistics & numerical data; D006301:Health Services Needs and Demand; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D058996:Quality Improvement / Q000706:statistics & numerical data; D061665:Time-to-Treatment / Q000592:standards / Q000706:statistics & numerical data; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents
references.citation: J Clin Oncol. 1992 Feb;10(2):316-22
references.pmid: 1732432
references.citation: Clin Infect Dis. 2011 Feb 15;52(4):e56-93
references.pmid: 21258094
references.citation: J Clin Oncol. 2000 Aug;18(16):3038-51
references.pmid: 10944139
references.citation: Pediatr Blood Cancer. 2012 Sep;59(3):431-5
references.pmid: 22147665
references.citation: Oncol Nurs Forum. 2004 Jul 13;31(4):711-5
references.pmid: 15252427
references.citation: JAMA. 2008 Feb 13;299(6):685-7
references.pmid: 18270357
references.citation: Ann Hematol. 2008 Feb;87(2):139-45
references.pmid: 17938926
references.citation: Cancer. 2005 May 1;103(9):1916-24
references.pmid: 15751024
references.citation: Curr Oncol. 2011 Dec;18(6):280-4
references.pmid: 22184489
references.citation: Clin J Oncol Nurs. 2002 Nov-Dec;6(6):337-40
references.pmid: 12434465
references.citation: Br J Haematol. 2011 Jun;153(6):773-9
references.pmid: 21517822
references.citation: Cancer. 2006 May 15;106(10):2258-66
references.pmid: 16575919
references.citation: Crit Care Med. 2006 Jun;34(6):1589-96
references.pmid: 16625125